

AMERADA HESS CORP

Form 144

June 15, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker.

1(a) NAME OF ISSUER (Please type or print)

Amerada Hess Corporation

1(b) IRS IDENT. NO.

13-4921002

1(c) S.E.C. FILE NO.

1-1204

1(d) ADDRESS OF ISSUER STREET

1185 Avenue of the Americas

CITY STATE ZIP CODE

New York NY 10036

1(e) TELEPHONE

AREA CODE | NUMBER

212 | 997-8500

2(a) NAME OF PERSON FOR WHOSE ACCOUNT THE SECURITIES ARE TO BE SOLD

J. Barclay Collins

2(b) IRS IDENT. NO.

2(c) RELATIONSHIP TO ISSUER

Director and Officer

2(d) ADDRESS STREET

1185 Avenue of the Americas

CITY STATE ZIP CODE

New York NY 10036

Edgar Filing: AMERADA HESS CORP - Form 144

INSTRUCTIONS: The person filing this notice should contact the issuer to obtain the I.R.S. Identification Number and the S.E.C. File Number.

3(a) Title of the Class of Securities To Be Sold

Common Stock par value \$1.00 per share

3(b) Name and Address of Each Broker Through Whom the Securities are to be Offered or Each Market Maker who is Acquiring the Securities

National Financial Services LLC
82 Devonshire Street
Boston, MA 02109

SEC USE ONLY

Broker-Dealer File Number

3(c) Number of Shares or Other Units To Be Sold
(See instr. 3(c))

2,000

3(d) Aggregate Market Value
(See instr. 3(d))

\$214,680.00 (as of close on 6/14/2005)

3(e) Number of Shares or Other Units Outstanding
(See instr. 3(e))

91,652,580

3(f) Approximate Date of Sale
(See instr. 3(f))
(MO. DAY YR.)

Commencing on or after 6/15/2005

3(g) Name of Each Securities Exchange
(See instr. 3(g))

New York Stock Exchange

INSTRUCTIONS:

1. (a) Name of issuer
(b) Issuer's I.R.S. Identification Number
(c) Issuer's S.E.C. file number, if any
(d) Issuer's address, including zip code
(e) Issuer's telephone number, including area code
2. (a) Name of person for whose account the securities are to be sold
(b) Such person's I.R.S. identification number, if such person is an entity
(c) Such person's relationship to the issuer (e.g., officer, director,

Edgar Filing: AMERADA HESS CORP - Form 144

- 10% stockholder, or member of immediate family of any of the foregoing)
- (d) Such person's address, including zip code
3. (a) Title of the class of securities to be sold
- (b) Name and address of each broker through whom the securities are intended to be sold
 - (c) Number of shares or other units to be sold (if debt securities, give the aggregate face amount)
 - (d) Aggregate market value of the securities to be sold as of a specified date within 10 days prior to the filing of this notice
 - (e) Number of shares or other units of the class outstanding, or if debt securities the face amount thereof outstanding, as shown by the most recent report or statement published by the issuer
 - (f) Approximate date on which the securities are to be sold
 - (g) Name of each securities exchange, if any, on which the securities are intended to be sold

TABLE I - SECURITIES TO BE SOLD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

Title of Class	Common Stock par value \$1.00 per share
Date you Acquired	To be acquired upon exercise of option on unrestricted stock expected to commence on or after 6/15/2005
Nature of Acquisition Transaction	Exercise of option on unrestricted stock
Name of Person from Whom Acquired (If gift, also give date donor acquired)	Amerada Hess Corporation
Amount of Securities Acquired	2,000
Date of Payment	On or after 6/15/2005
Nature of Payment	Cash

INSTRUCTIONS: If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the

Edgar Filing: AMERADA HESS CORP - Form 144

table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

TABLE II - SECURITIES SOLD DURING THE PAST 3 MONTHS

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

Name and Address of Seller

J. Barclay Collins
c/o Amerada Hess Corporation
1185 Avenue of the Americas
New York, NY 10036

Title of Securities Sold

Common Stock par value \$1.00 per share

Date of Sale

From 5/19/05 to 6/15/2005

Amount of Securities Sold

Gross Proceeds

17,000

\$1,638,450.00

REMARKS:

INSTRUCTIONS:

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

ATTENTION:

The person for whose account the securities to which this notice relates are to sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed.

Edgar Filing: AMERADA HESS CORP - Form 144

6/15/2005

/s/J. Barclay Collins

DATE OF NOTICE

(SIGNATURE)

The notice shall be signed by the person for whose account the securities are to be sold. At least one copy of the notice shall be manually signed. Any copies not manually signed shall bear typed or printed signatures.

ATTENTION: International misstatements or omission of facts constitute
Federal Criminal Violations (See 18 U.S.C. 1001)

STYLE="font-family:Times New Roman" SIZE="1" COLOR="#FFFFFF">the effects of the proposed combination of Valeant and Allergan, including the combined company's future financial condition, operating results, strategy and plans; the effects of governmental regulation on our business or potential business combination transactions; the ability to obtain regulatory approvals and meet other conditions to the offer, including the necessary stockholder approval, on a timely basis;

